{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:37Z","timestamp":1792449577724,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473840"],"award-info":[{"award-number":["82473840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M764303"],"award-info":[{"award-number":["2024M764303"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005054","name":"Nantong University","doi-asserted-by":"publisher","award":["KFJN2535"],"award-info":[{"award-number":["KFJN2535"]}],"id":[{"id":"10.13039\/501100005054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118574","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:06:58Z","timestamp":1767974818000},"page":"118574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3\/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluation"],"prefix":"10.1016","volume":"305","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4386-0911","authenticated-orcid":false,"given":"Fansheng","family":"Ran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-011X","authenticated-orcid":false,"family":"Yong Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118574_bib1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118574_bib2","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/stmcls\/sxac052","article-title":"An interferon-\u03b3\/FLT3 axis positively regulates hematopoietic progenitor cell expansion from human pluripotent stem cells","volume":"40","author":"Kitajima","year":"2022","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2026.118574_bib3","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1182\/blood.V128.22.3357.3357","article-title":"Evaluating on-target toxicity of hematopoietic-targeting cars demonstrates rarget-nonspecific suppression of marrow progenitors","volume":"128","author":"Sauter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118574_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.18877","article-title":"Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy","volume":"202","author":"Ge","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2026.118574_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/CU9.0000000000000222","article-title":"Prostate cancer genotyping for risk stratification and precision treatment","volume":"18","author":"Kumar","year":"2024","journal-title":"Curr. Urol."},{"key":"10.1016\/j.ejmech.2026.118574_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential targeting of FLT3 acute myeloid leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2026.118574_bib7","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118574_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2019.09.023","article-title":"A prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation","volume":"26","author":"Pratz","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejmech.2026.118574_bib9","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","article-title":"Potent targeting of FLT3 mutations in AML","volume":"4","author":"Levis","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2026.118574_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CMAR.S196568","article-title":"Profile of quizartinib for the treatment of adult patients with relapsed\/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date","volume":"12","author":"Fletcher","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejmech.2026.118574_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116902","article-title":"A new strategy for overcoming drug resistance in liver cancer: epigenetic regulation","volume":"176","author":"Su","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118574_bib12","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.118574_bib13","doi-asserted-by":"crossref","first-page":"12460","DOI":"10.1021\/acs.jmedchem.0c00830","article-title":"Thirty years of HDAC inhibitors: 2020 insight and hindsight","volume":"63","author":"Ho","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118574_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33052","article-title":"Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat","volume":"10","author":"El Omari","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.118574_bib15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/hon.2691","article-title":"Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: real-life data from a national multicenter observational study","volume":"37","author":"Shimony","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.118574_bib16","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/1078-0432.CCR-14-3119","article-title":"FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"21","author":"Lee","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118574_bib17","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2174\/1568009617666170630124643","article-title":"The safety, efficacy and therapeutic potential of histone deacetylase inhibitors with special reference to panobinostat in gastrointestinal tumors: a review of preclinical and clinical studies","volume":"18","author":"Singh","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2026.118574_bib18","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1182\/blood-2018-99-114598","article-title":"The novel HDAC inhibitor chidamide synergizes with rituximab to inhibit DLBCL tumor growth in vitro and in vivo by up-regulating CD20 expression","volume":"132","author":"Guan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118574_bib19","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3390\/ijms19071939","article-title":"Therapeutic opportunities of targeting histone deacetylase isoforms to eradicate cancer stem cells","volume":"19","author":"Lin","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118574_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/jcbfm.2010.195","article-title":"Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition","volume":"31","author":"Wang","year":"2011","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejmech.2026.118574_bib21","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of hydrazide-bearing HDACIs based on panobinostat and their p53 and FLT3-ITD dependency in antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118574_bib22","article-title":"PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118574_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00204-021-03174-1","article-title":"Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3","volume":"96","author":"Wachholz","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejmech.2026.118574_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-139696","article-title":"Antimetabolic cooperativity with l-Asparaginase and tyrosine kinase inhibitor quizartinib to eradicate persistant FLT3-ITD leukemic cells","volume":"136","author":"Fovez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.118574_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106479","article-title":"Synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK\/FLT3 dual-target inhibitors against acute myeloid leukemia","volume":"134","author":"Ran","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118574_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115759","article-title":"Rational discovery of dual FLT3\/HDAC inhibitors as a potential AML therapy","volume":"260","author":"Wang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118574_bib27","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1021\/acs.jmedchem.8b01013","article-title":"Histone deacetylase 6-Selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity","volume":"61","author":"Porter","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118574_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00705-016-3130-2","article-title":"Roles of reactive oxygen species in cell signaling pathways and immune responses to viral infections","volume":"162","author":"Li","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.ejmech.2026.118574_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/978-1-4939-7831-1_22","article-title":"Relation between mitochondrial membrane potential and ROS formation","volume":"1782","author":"Suski","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2026.118574_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-017-1231-7","article-title":"CDK4\/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest","volume":"15","author":"Wang","year":"2017","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.118574_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114913","article-title":"Development of novel hydrazidoarylaminopyrimidine-based BTK\/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects","volume":"245","author":"Ran","year":"2023","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:47:11Z","timestamp":1773971231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S022352342600019X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118574","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel aminopyrimidine-hydroxamate derivatives as dual FLT3\/HDAC inhibitors: Design, synthesis, and anti-hematologic malignancy evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118574"}}